Arrhythmia
Read Time: 2 mins

53/Improving understanding of lesion parametrics in high-power short-duration ablation

Published Online: October 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr53
Authors: G Panchal (Presenting Author) – Glenfield hospital, Leicester; A Mavilakandy – Glenfield hospital, Leicester; I Koev – Glenfield hospital, Leicester; A Kotb – Glenfield hospital, Leicester; M Ibrahim – Glenfield hospital, Leicester; M Lazdam – Glenfield hospital, Leicester; SH Chin – Glenfield hospital, Leicester; A Sandilands – Glenfield hospital, Leicester; R Somani – Glenfield hospital, Leicester; GA Ng – Glenfield hospital, Leicester
Quick Links:
Article
Article Information
Article:

Background: Pulmonary vein isolation (PVI) is the gold standard management for patients with atrial fibrillation (AF) refractory to medical therapy. Contact-force (CF) sensing very-high-power short-duration (vHPSD) radiofrequency (RF) ablation (90 W/4 seconds) has emerged as a novel ablation modality. Previous RF ablation utilized Ablation Index (AI) as a surrogate marker of lesion quality to guide the operator, which is not utilized in QMODE+ (vHPSD) and thus, there is limited guidance on effective lesion formation. In this study, we investigated the correlation between certain lesion parameters to identify relationships and potential determinants for effective lesion formation. Furthermore, we studied the relationship between different anatomical locations on these parameters to gain further insight.

Method: A total of 60 consecutive AF patients (42 males, age 61.5 ± 9.06 years, 63% paroxysmal AF) underwent first-time PVI using QMODE+. All wide antral circumferential ablation (WACA) QMODE+ lesions (n=6040) were analysed for force-time integral (FTI), impedance drop, average CF, maximum temperature attained, and anatomical location. The anatomical regions assessed across both left and right WACA were posterior-superior (region 1-2), posterior-inferior (region 3-4), anterior-inferior (region 5-6), and anterior-superior (region 7-8), and pulmonary vein carina (region 9). All pulmonary veins (PVs) were subsequently checked with pacing manoeuvres to examine for gaps in ablation lesions and adenosine for acute pulmonary vein reconnection post-ablation.

Results: PVI was successful in all patients while first-pass isolation was observed in 30 patients (50%). A total of 6,040 lesions were performed, with 2,968 and 3,072 lesions in the left and right WACA, respectively. The average CF exhibited a positive correlation with maximum temperature attained and impedance drop (p<0.0001) while displaying a negative correlation with FTI (p<0.0001) (Figure 1). The PV carina (region 9) of the right WACA had the smallest impedance drop (p<0.0001) while the PV carina of the left WACA exhibited the lowest average CF and temperature attained (p<0.0001) (Figure 2). The highest number of gaps or acute reconnection (17 out of 30 patients) were seen in the region of the left pulmonary vein carina (p<0.0001).

Conclusion: To our knowledge, this is the first study that has investigated the characteristics of vHPSD ablation lesions according to different anatomical regions in the left atrium. CF was positively correlated with maximum temperature and impedance drop but negatively correlated with FTI. This is very unique to temperature-controlled ablation to reduce complications. Furthermore, ablation at both right and left PV carina demonstrated lower impedance drop and average CF which may explain difficult catheter positioning as well as thicker tissue. This study elucidates the relationship between the anatomical region, contact force, temperature and impedance drop, and will facilitate optimization for effective vHPSD lesion formation.

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72